Substance Abuse Therapeutics Market to 2018 - Effective Drug Therapies in the Treatment of Alcohol and Opioid Dependence Offer Significant Market Opportunities

Substance Abuse Therapeutics Market to 2018 - Effective Drug Therapies in the Treatment of Alcohol and Opioid Dependence Offer Significant Market Opportunities

Summary

GBI Research, leading business intelligence provider has released its latest research report, entitled “Substance Abuse Therapeutics Market to 2018 - Effective Drug Therapies in the Treatment of Alcohol and Opioid Dependence Offer Significant Market Opportunities”. The report provides insights into the substance abuse therapeutics market including market forecasts up to 2018. It provides an in-depth analysis of the major substance abuse indications, which include nicotine addiction, alcohol dependence and opioid and cocaine abuse, as well as insights into the substance abuse therapeutics R&D pipeline. In addition, it analyzes the competitive landscape through the analysis of M&A and licensing deals.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research finds that the substance abuse therapeutics market in the top seven markets was valued at $8.8 billion in 2011, increasing at a CAGR of 4.9% during the review period 2004–2011. The market is projected to witness moderate growth of 5.3% during the 2011–2018 forecast period to reach $12.7 billion. The moderate growth of the market can be attributed to the presence of generics in the market, low compliance with therapy due to the nature of addiction and the lack of innovative products in the pipeline. However, indications such as cocaine addiction, which currently have no approved products, are expected to see entries to the market and high-priced products such as Champix for smoking cessation will not see patent expiry in the forecast period.

Scope

- Data and analysis on the substance abuse therapeutics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the substance abuse therapeutics market from 2004-2011 with forecasts to 2018.
- Market data on the therapeutic landscape, which covers nicotine addiction, alcohol dependence and opioid and cocaine abuse. This includes market size, annual cost of therapy, treatment flow algorithm.
- Key drivers and restraints that have had a significant impact on the market and on each indication.
- The competitive landscape of the global substance abuse therapeutics market, which includes companies such as Pfizer, GSK, Forest Laboratories, Alkermes and Reckitt Benckiser.
- Key M&A activities and licensing agreements that took place from 2007 to 2011 in the global substance abuse therapeutics market.

Reasons to buy

- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the potential region and substance abuse therapeutics market segments poised for strong growth.
- Create a more tailored country strategy through the understanding of key drivers and barriers of the global substance abuse therapeutics market.
- Develop key strategic initiatives by understanding the key focus areas and top selling therapeutics of leading companies.
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 10
2 Substance Abuse Therapeutics Market to 2018 - Introduction 12
2.1 Overview 12
3 Substance Abuse Therapeutics Market to 2018 - Market Overview 14
3.1 Introduction 14
3.2 Revenue Forecasts for Substance Abuse Therapeutics Market 14
3.2.1 Revenue 14
3.2.2 Annual Cost of Treatment 16
3.3 Treatment Usage Patterns 17
3.3.1 Diseased Population 17
3.3.2 Diagnosed Population 18
3.3.3 Prescription Population 19
3.4 Drivers and Barriers for Substance Abuse Therapeutics Market 20
3.4.1 Drivers 20
3.4.2 Barriers 21
4 Substance Abuse Therapeutics Market to 2018 - Geographical Landscape 22
4.1 The US 22
4.1.1 Revenue 22
4.1.2 Annual Cost of Treatment 23
4.1.3 Treatment Usage Patterns 24
4.1.4 Diagnosed Population 25
4.1.5 Prescription Population 26
4.2 Top Five Countries of Europe 27
4.2.1 Revenue 27
4.2.2 Annual Cost of Treatment 28
4.2.3 Treatment Usage Patterns 29
4.3 Japan 32
4.3.1 Revenue 32
4.3.2 Annual Cost of Treatment 34
4.3.3 Treatment Usage Patterns 35
5 Substance Abuse Therapeutics Market to 2018 - Nicotine Addiction Therapeutics Market 38
5.1 Introduction 38
5.1.1 Treatment Flow Algorithm 39
5.1.2 Opportunities/Unmet Needs 39
5.1.3 Revenue 40
5.1.4 Annual Cost of Treatment 42
5.1.5 Treatment Usage Patterns 43
5.1.6 Drivers and Barriers for the Nicotine Addiction Market 46
5.1.7 Drivers 46
5.1.8 Barriers 47
5.2 Marketed Products 48
5.2.1 Chantix (varenicline) 48
5.2.2 Zyban (buproprion hydrochloride) 48
5.2.3 Nicotine Replacement Therapies 48
6 Substance Abuse Therapeutics Market to 2018 - Alcohol Dependence Therapeutics Market 50
6.1 Introduction 50
6.1.1 Treatment Flow 51
6.1.2 Opportunities/Unmet Needs 52
6.1.3 Revenue 52
6.1.4 Annual Cost of Treatment 54
6.1.5 Treatment Usage Patterns 55
6.2 Drivers and Barriers for Alcohol Dependence Therapeutic Market 58
6.2.1 Drivers 58
6.2.2 Barriers 59
6.3 Marketed Products 59
6.3.1 Detoxification treatment options 59
6.3.2 Campral (acamprosate calcium) 59
6.3.3 Antabuse (disulfurum) 60
6.3.4 Vivitrol (naltrexone) 60
7 Substance Abuse Therapeutics Market to 2018 - Drug Abuse Therapeutics Market 61
7.1 Introduction 61
7.1.1 Opioid Abuse 61
7.1.2 Cocaine Abuse 62
7.1.3 Treatment Flow Algorithm 62
7.1.4 Opportunities/Unmet Needs 63
7.2 Revenues 63
7.2.1 Annual Cost of Therapy 65
7.2.2 Treatment Usage Patterns 66
7.3 Drivers and Barriers for Drug Abuse 69
7.3.1 Drivers 69
7.3.2 Barriers 69
7.4 Marketed Drugs - Opioid Abuse 70
7.4.1 Methadone 70
7.4.2 Suboxone (buprenorphine and naloxone) 70
7.4.3 Buprenorphine Hydrochloride 70
7.4.4 Vivitrol (naltrexone) 70
7.5 Marketed Products - Cocaine Abuse 70
7.5.1 Overview 70
7.5.2 Sabril (vigabatrin) 70
7.5.3 Fluoxetine 71
7.5.4 Disulfiram (Antabuse) 71
7.5.5 Naltrexone 71
7.5.6 Topiramate 71
7.5.7 Amantadine 71
7.5.8 Baclofen 71
7.5.9 Modafinil 71
8 Substance Abuse Therapeutics Market to 2018 - Product Pipeline Analysis 72
8.1 R&D Pipeline - Nicotine Addiction Therapeutics Market 72
8.1.1 Pre-clinical and Discovery Phase 72
8.1.2 Phase I 72
8.1.3 Phase II 72
8.1.4 Promising Pipeline Molecules 72
8.2 R&D Pipeline - Alcohol Dependence Therapeutics Market 73
8.2.1 Pre-clinical and Discovery Phase 73
8.2.2 Phase I 73
8.2.3 Phase II 73
8.2.4 NDA Filed 73
8.2.5 Promising Molecules in the Pipeline 74
8.2.6 NS11 74
8.3 R&D Pipeline - Drug Abuse Therapeutics Market 75
8.3.1 Pre-clinical and Discovery Phase 75
8.3.2 Phase I 75
8.3.3 Phase II 75
8.3.4 Phase III 75
8.3.5 Promising Molecules in the Pipeline 76
9 Substance Abuse Therapeutics Market to 2018 - Competitive Landscape 77
9.1 GlaxoSmithKline 77
9.1.1 Overview 77
9.1.2 Major Products in the Substance Abuse Therapeutics Market 77
9.1.3 SWOT Analysis 78
9.2 Pfizer 78
9.2.1 Overview 78
9.2.2 Major Products in the Substance Abuse Therapeutics Market 78
9.2.3 SWOT Analysis 79
9.3 Alkermes 80
9.3.1 Overview 80
9.3.2 Major Products in the Substance Abuse Therapeutics Market 80
9.3.3 SWOT Analysis 80
9.4 Forest Laboratories, Inc. 81
9.4.1 Overview 81
9.4.2 Major Products in the Substance Abuse Therapeutics Market 81
9.4.3 SWOT Analysis 81
9.5 Teva Pharmaceuticals 82
9.5.1 Overview 82
9.5.2 Major Products in the Substance Abuse Therapeutics Market 82
9.5.3 SWOT Analysis 82
9.6 Reckitt Benckiser Pharmaceuticals 83
9.6.1 Overview 83
9.6.2 Major Products in the Substance Abuse Therapeutics Market 83
9.6.3 SWOT Analysis 84
10 Substance Abuse Therapeutics Market to 2018 - Strategic Consolidations 85
10.1 Mergers and Acquisitions (M&A) 85
10.1.1 Deals by Year 85
10.1.2 Deals by Geography 86
10.1.3 Major Mergers and Acquisitions, 2007-2012 86
10.2 Licensing Agreements 87
10.2.1 Deals by Year 87
10.2.2 Deals by Geography 88
10.2.3 Major Licensing and Co-Development Agreements, 2007-2012 88
11 Substance Abuse Therapeutics Market to 2018 - Appendix 90
11.1 Market Definitions 90
11.2 Abbreviations 90
11.3 Bibliography 91
11.4 Research Methodology 93
11.4.1 Coverage 93
11.4.2 Secondary Research 93
11.4.3 Primary Research 93
11.5 Therapeutic Landscape 94
11.5.1 Epidemiology-based Forecasting 94
11.5.2 Market Size by Geography 96
11.6 Geographical Landscape 97
11.7 Pipeline Analysis 97
11.8 Competitive Landscape 97
11.8.1 Expert Panel Validation 97
11.9 Contact Us 97
11.10 Disclaimer 97

1.1 List of Tables
Table 1: Substance Abuse Therapeutics Market, Global, Revenue ($bn), 2004-2011 15
Table 2: Substance Abuse Therapeutics Market, Global, Revenue Forecasts ($bn), 2011-2018 15
Table 3: Substance Abuse Therapeutics Market, Global, ACT ($), 2004-2011 16
Table 4: Substance Abuse Therapeutics Market, Global, ACT ($), 2011-2018 16
Table 5: Substance Abuse Therapeutics Market, Global, Diseased Population (Millions), 2004-2011 17
Table 6: Substance Abuse Therapeutics Market, Global, Diseased Population (Millions), 2011-2018 17
Table 7: Substance Abuse Therapeutics Market, Global, Diagnosed Population (millions), 2004-2011 18
Table 8: Substance Abuse Therapeutics Market, Global, Diagnosed Population (millions), 2011-2018 18
Table 9: Substance Abuse Therapeutics Market, Global, Prescription Population (millions), 2004-2011 19
Table 10: Substance Abuse Therapeutics Market, Global, Prescription Population (millions), 2011-2018 19
Table 11: Substance Abuse Therapeutics Market, The US, Revenue ($bn), 2004-2011 22
Table 12: Substance Abuse Therapeutics Market, The US, Revenue Forecasts ($bn), 2011-2018 22
Table 13: Substance Abuse Therapeutics Market, The US, ACT ($), 2004-2011 23
Table 14: Substance Abuse Therapeutics Market, The US, ACT ($), 2011-2018 23
Table 15: Substance Abuse Therapeutics Market, The US, Diseased Population (millions), 2004-2011 24
Table 16: Substance Abuse Therapeutics Market, The US, Diseased Population (millions), 2011-2018 24
Table 17: Substance Abuse Therapeutics Market, The US, Diagnosed Population (millions), 2004-2011 25
Table 18: Substance Abuse Therapeutics Market, The US, Diagnosed Population (millions), 2011-2018 25
Table 19: Substance Abuse Therapeutics Market, The US, Prescription Population (millions), 2004-2011 26
Table 20: Substance Abuse Therapeutics Market, The US, Prescription Population (millions), 2011-2018 26
Table 21: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2004-2011 27
Table 22: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2011-2018 27
Table 23: Substance Abuse Therapeutics Market, Top Five Countries of Europe, ACT ($), 2004-2011 28
Table 24: Substance Abuse Therapeutics Market, Top Five Countries of Europe, ACT ($), 2011-2018 28
Table 25: Substance Abuse Therapeutics Market, Top Five Countries of Europe Diseased Population (millions), 2004-2011 29
Table 26: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Diseased Population (millions), 2011-2018 29
Table 27: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Diagnosed Population (millions), 2004-2011 30
Table 28: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Diagnosed Population (millions), 2011-2018 31
Table 29: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Prescription Population (millions), 2004-2011 31
Table 30: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Prescription Population (millions), 2011-2018 32
Table 31: Substance Abuse Therapeutics Market, Japan, Revenue ($m), 2004-2011 32
Table 32: Substance Abuse Therapeutics Market, Japan, Revenue Forecasts ($m), 2011-2018 33
Table 33: Substance Abuse Therapeutics Market, Japan, ACT ($), 2004-2011 34
Table 34: Substance Abuse Therapeutics Market, Japan, ACT ($), 2011-2018 34
Table 35: Substance Abuse Therapeutics Market, Japan, Diseased Population (millions), 2004-2011 35
Table 36: Substance Abuse Therapeutics Market, Japan, Diseased Population (millions, 2011-2018 35
Table 37: Substance Abuse Therapeutics Market, Japan, Diagnosed Population (millions), 2004-2011 36
Table 38: Substance Abuse Therapeutics Market, Japan, Diagnosed Population (millions), 2011-2018 36
Table 39: Substance Abuse Therapeutics Market, Japan, Prescription Population (millions), 2004-2011 37
Table 40: Substance Abuse Therapeutics Market, Japan, Prescription Population (millions), 2011-2018 37
Table 41: Nicotine Addiction Therapeutics Market, Global, Revenue ($bn), 2004-2011 40
Table 42: Nicotine Addiction Therapeutics Market, Global, Revenue Forecasts ($bn), 2011-2018 40
Table 43: Nicotine Addiction Therapeutics Market, Global, ACT ($), 2004-2011 42
Table 44: Nicotine Addiction Therapeutics Market, Global, ACT ($), 2011-2018 42
Table 45: Nicotine Addiction Market, Global, Diseased Population (millions), 2004-2011 43
Table 46: Nicotine Addiction Therapeutics Market, Global, Diseased Population (millions), 2011-2018 43
Table 47: Nicotine Addiction Therapeutics Market, Global, Diagnosed Population (millions), 2004-2011 44
Table 48: Nicotine Addiction Therapeutics Market, Global, Diagnosed Population (millions), 2011-2018 44
Table 49: Nicotine Addiction Therapeutics Market, Global, Prescription Population (millions), 2004-2011 45
Table 50: Nicotine Addiction Therapeutics Market, Global, Prescription Population (millions), 2011-2018 45
Table 51: Alcohol Dependence Therapeutics Market, Global, Revenue ($m), 2004-2011 53
Table 52: Alcohol Dependence Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018 53
Table 53: Alcohol Dependence Therapeutics Market, Global, ACT ($), 2004-2011 54
Table 54: Alcohol Dependence Therapeutics Market, Global, ACT ($), 2011-2018 54
Table 55: Alcohol Dependence Therapeutic Market, Global, Diseased Population (millions), 2004-2011 55
Table 56: Alcohol Dependence Therapeutic Market, Global, Diseased Population (millions), 2011-2018 55
Table 57: Alcohol Dependence Therapeutics Market, Global, Diagnosed Population (millions), 2004-2011 56
Table 58: Alcohol Dependence Therapeutics Market, Global, Diagnosed Population (millions), 2011-2018 56
Table 59: Alcohol Dependence Therapeutics Market, Global, Prescription Population (000’), 2004-2011 57
Table 60: Alcohol Dependence Therapeutics Market, Global, Prescription Population (000’), 2011-2018 57
Table 61: Drug Abuse Therapeutics Market, Global, Revenue ($bn), 2004-2011 64
Table 62: Drug Abuse Therapeutics Market, Global, Revenue Forecasts ($bn), 2011-2018 64
Table 63: Drug Abuse Therapeutics Market, Global, Average ACT ($), 2004-2011 65
Table 64: Drug Abuse Therapeutics Market, Global, Average ACT ($), 2011-2018 65
Table 65: Drug Abuse Therapeutics Market, Global, Diseased Population (millions), 2004-2011 66
Table 66: Drug Abuse Therapeutics Market, Global, Diseased Population (millions), 2011-2018 66
Table 67: Drug Abuse Therapeutics Market, Global, Diagnosed Population (millions), 2004-2011 67
Table 68: Drug Abuse Therapeutics Market, Global, Diagnosed Population (millions), 2011-2018 67
Table 69: Drug Abuse Therapeutics Market, Global, Prescription Population (millions), 2004-2011 68
Table 70: Drug Abuse Therapeutics Market, Global, Prescription Population (millions), 2011-2018 68
Table 71: Nicotine Addiction Therapeutics Market, Global, R&D Pipeline in Pre-clinical and Discovery Phase, 2011 72
Table 72: Nicotine Addiction Therapeutics Market, Global, R&D Pipeline in Phase I, 2011 72
Table 73: Nicotine Addiction Therapeutics Market, Global, R&D Pipeline in Phase II, 2011 72
Table 74: Alcohol Dependence Therapeutics Market, Global, R&D Pipeline in Pre-clinical and Discovery Phase, 2011 73
Table 75: Alcohol Dependence Therapeutics Market, Global, R&D Pipeline in Phase I, 2011 73
Table 76: Alcohol Dependence Therapeutics Market, Global, R&D Pipeline in Phase II, 2011 73
Table 77: Alcohol Dependence Therapeutics Market, Global, R&D Pipeline in NDA Filed, 2011 73
Table 78: Drug Abuse Therapeutics Market, Global, Pre-clinical, 2011 75
Table 79: Drug Abuse Therapeutics Market, Global, Phase I, 2011 75
Table 80: Drug Abuse Therapeutics Market, Global, Phase II, 2011 75
Table 81: Drug Abuse Therapeutics Market, Global, Phase III, 2011 75

1.2 List of Figures
Figure 1: Substance Abuse Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018 14
Figure 2: Substance Abuse Therapeutics Market, Global, ACT ($), 2004-2018 16
Figure 3: Substance Abuse Therapeutics Market, Global, Diseased Population (Millions), 2004-2018 17
Figure 4: Substance Abuse Therapeutics Market, Global, Diagnosed Population (millions), 2004-2018 18
Figure 5: Substance Abuse Therapeutics Market, Global, Prescription Population (millions), 2004-2018 19
Figure 6: Substance Abuse Therapeutics Market, Drivers and Barriers, 2011 20
Figure 7: Substance Abuse Therapeutics Market, The US, Revenue Forecasts ($bn), 2004-2018 22
Figure 8: Substance Abuse Therapeutics Market, The US, ACT ($), 2004-2018 23
Figure 9: Substance Abuse Therapeutics Market, The US, Diseased Population (millions), 2004-2018 24
Figure 10: Substance Abuse Therapeutics Market, The US, Diagnosed Population (millions), 2004-2018 25
Figure 11: Substance Abuse Therapeutics Market, The US, Prescription Population (millions), 2004-2018 26
Figure 12: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2004-2018 27
Figure 13: Substance Abuse Therapeutics Market, Top Five Countries of Europe, ACT ($), 2004-2018 28
Figure 14: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Diseased Population (millions), 2004-2018 29
Figure 15: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Diagnosed Population (millions), 2004-2018 30
Figure 16: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Prescription Population (millions), 2004-2018 31
Figure 17: Substance Abuse Therapeutics Market, Japan, Revenue Forecasts ($m), 2004-2018 32
Figure 18: Substance Abuse Therapeutics Market, Japan, ACT ($), 2004-2018 34
Figure 19: Substance Abuse Therapeutics Market, Japan, Diseased Population (millions), 2004-2018 35
Figure 20: Substance Abuse Therapeutics Market, Japan, Diagnosed Population (millions), 2004-2018 36
Figure 21: Substance Abuse Therapeutics Market, Japan, Prescription Population (millions), 2004-2018 37
Figure 22: Nicotine Addiction Therapeutics Market, Treatment Flow Algorithm 39
Figure 23: Nicotine Addiction Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018 40
Figure 24: Nicotine Addiction Therapeutics Market, Global, ACT ($), 2004-2018 42
Figure 25: Nicotine Addiction Therapeutics Market, Global, Diseased Population (millions), 2004-2018 43
Figure 26: Nicotine Addiction Therapeutics Market, Global, Diagnosed Population (millions), 2004-2018 44
Figure 27: Nicotine Addiction Therapeutics Market, Global, Prescription Population (millions), 2004-2018 45
Figure 28: Nicotine Addiction Therapeutics Market, Global, Drivers and Barriers, 2011 46
Figure 29: Alcohol Dependence Therapeutics Market, Treatment Flow Algorithm 51
Figure 30: Alcohol Dependence Therapeutics Market, Global, Revenue Forecasts ($m), 2004-2018 52
Figure 31: Alcohol Dependence Therapeutics Market, Global, ACT ($), 2004-2018 54
Figure 32: Alcohol Dependence Therapeutics Market, Global, Diseased Population (millions), 2004-2018 55
Figure 33: Alcohol Dependence Therapeutics Market, Global, Diagnosed Population (millions), 2004-2018 56
Figure 34: Alcohol Dependence Therapeutics Market, Global, Prescription Population (000’), 2004-2018 57
Figure 35: Alcohol Dependence Therapeutics Market, Global, Drivers and Barriers, 2011 58
Figure 36: Drug Abuse Therapeutics Market, Treatment Flow Algorithm 62
Figure 37: Drug Abuse Therapeutics Market, Global, Revenue ($bn), 2004-2018 63
Figure 38: Drug Abuse Therapeutics Market, Global, ACT ($), 2004-2018 65
Figure 39: Drug Abuse Therapeutics Market, Global, Diseased Population (millions), 2004-2018 66
Figure 40: Drug Abuse Therapeutics Market, Global, Diagnosed Population (millions), 2004-2018 67
Figure 41: Drug Abuse Therapeutics Market, Global, Prescription Population (millions), 2004-2018 68
Figure 42: Drug Abuse Therapeutics Market, Global, Drivers and Barriers, 2011 69
Figure 43: Substance Abuse Therapeutics Market, SWOT Analysis, GSK, 2011 78
Figure 44: Substance Abuse Therapeutics Market, SWOT Analysis, Pfizer, 2011 79
Figure 45: Substance Abuse Therapeutics Market, SWOT Analysis, Alkermes, 2011 80
Figure 46: Substance Abuse Therapeutics Market, SWOT Analysis, Forest Laboratories Inc., 2011 81
Figure 47: Substance Abuse Therapeutics Market, SWOT Analysis, Teva Pharmaceutical, 2011 82
Figure 48: Substance Abuse Therapeutics Market, SWOT Analysis, Reckitt Benckiser, 2011 84
Figure 49: Substance Abuse Therapeutics Market, Global, Major M&A Deals By Year, 2007-2012 85
Figure 50: Substance Abuse Therapeutics Market, Global, Major M&A Deals By Geography, 2007-2012 86
Figure 51: Substance Abuse Therapeutics Market, Global, R&D Licensing Deals By Year, 2007-2012 87
Figure 52: Substance Abuse Therapeutics Market, Global, Major R&D Licensing Deals By Geography, 2007-2012 88
Figure 53: GBI Research Market Forecasting Model 96